Medical Health Aged Care 29/08/2023 14:02

UNSW expert available to comment on PBAC rejection of Mounjaro

UNSW Sydney < 1 mins read

< 1 mins read

The Pharmaceutical Benefits Advisory Committee (PBAC) has rejected the application to subsidise Mounjaro, the diabetes drug that can also be used for weight loss (similar to Ozempic).

Dr Namson Lau is available to provide expert commentary, and can be contacted at namson.lau@sydney.edu.au.

Dr. Namson Lau is a Conjoint Senior Lecturer, UNSW Sydney, and consultant endocrinologist at Liverpool and Royal Prince Alfred Hospitals. His PhD was in neuro-endocrine regulation of appetite and weight and he has extensive clinical and research expertise in type 2 diabetes, complex obesity and cardio-metabolic management.

More from this category

Environment, Medical Health Aged Care
01/12/2023
10:43

West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

Medical Health Aged Care
01/12/2023
10:12

Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

Contains:

Medical Health Aged Care, Research Development
01/12/2023
09:17

Aegros

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.

Book a demo Explore our plans